| Size | Price | |
|---|---|---|
| Other Sizes |
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Peak plasma concentrations are reached within 15 minutes after intravenous administration. Elimination route is not specified. Volume of distribution after intravenous administration is 35-82 L. Systemic clearance is 0.2-0.4 L/min. Metabolism/Metabolites Metabolism has not been determined. Biological Half-Life The half-life is approximately 1.5 hours. |
|---|---|
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation There is currently no information regarding the clinical use of polidocanol during lactation. While polidocanol is unlikely to have adverse effects on breastfed infants, international guidelines recommend suspending breastfeeding for 2 days after sclerotherapy. ◉ Effects on Breastfed Infants No published information found as of the revision date. ◉ Effects on Lactation and Breast Milk No published information found as of the revision date. Protein Binding Plasma protein binding was not measured. |
| Additional Infomation |
Polidocanol is a hydroxyl polyether, a derivative of nonyl glycol, with its terminal hydroxyl group replaced by a dodecyl (lauryl) group. It is a nonionic surfactant, hepatotoxic drug, and sclerosing agent. Its function is similar to that of nonyl glycol. Polidocanol is a sclerosing agent suitable for treating simple spider veins (varicose veins ≤1 mm in diameter) and simple reticular veins (varicose veins 1 to 3 mm in diameter) of the lower extremities. Its trade names are Asclera and Varitena. The structural formula of Polidocanol is C12H25(OCH2CH2)nOH, with an average degree of polymerization (n) of approximately 9 and an average molecular weight of approximately 600. Polidocanol is a lauryl alkyl polyethylene glycol ether with sclerosing effects and potential antitumor activity. Intralesional injection of Polidocanol can induce endothelial cell damage by disrupting calcium signaling and nitric oxide pathways. Following endothelial injury, platelets aggregate at the site of injury and attach to the vein wall, forming a dense network of platelets, cell debris, and fibrin that obstructs the vessel. Inducing endothelial cell damage in melanoma metastases may trigger an antitumor response in untreated peripheral lesions and inhibit the growth of metastases and other skin lesions.
See also: Ethylene oxide (containing monomers)...See more... Drug IndicationsPolydocaine is a sclerosing agent indicated for the treatment of simple spider angiomas and simple reticular veins of the lower extremities. FDA Label Mechanism of ActionAfter administration, polidocaine locally damages the vascular endothelium. Following endothelial injury, platelets aggregate at the site of injury and attach to the vein wall, eventually forming a dense network of platelets, cell debris, and fibrin that obstructs the vessel. Eventually, the vessel is replaced by connective tissue fibrous tissue. PharmacodynamicsPolydocaine has a concentration- and volume-dependent damaging effect on the vascular endothelium. |
| Molecular Formula |
C30H62O10
|
|---|---|
| Molecular Weight |
582.80728
|
| Exact Mass |
582.434
|
| CAS # |
9043-30-5
|
| Related CAS # |
9043-30-5
|
| PubChem CID |
656641
|
| Appearance |
Colorless to light yellow liquid（Density：1.05 g/cm3）
|
| Density |
1.05 g/mL at 25 °C(lit.)
|
| Boiling Point |
615.9±50.0 °C at 760 mmHg
|
| Melting Point |
41-45ºC(lit.)
|
| Flash Point |
326.3±30.1 °C
|
| Vapour Pressure |
0.0±4.0 mmHg at 25°C
|
| Index of Refraction |
n20/D 1.461
|
| LogP |
2.18
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
37
|
| Heavy Atom Count |
40
|
| Complexity |
431
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCCCCCCCCCCC
|
| InChi Key |
ONJQDTZCDSESIW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C30H62O10/c1-2-3-4-5-6-7-8-9-10-11-13-32-15-17-34-19-21-36-23-25-38-27-29-40-30-28-39-26-24-37-22-20-35-18-16-33-14-12-31/h31H,2-30H2,1H3
|
| Chemical Name |
2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7158 mL | 8.5791 mL | 17.1583 mL | |
| 5 mM | 0.3432 mL | 1.7158 mL | 3.4317 mL | |
| 10 mM | 0.1716 mL | 0.8579 mL | 1.7158 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
